HealthEquity, Inc. (HQY) Stock Analysis
Is HQY a good investment?
HealthEquity, Inc. (HQY) has a Plutrex AI rating of 79.0/100 as of July 10, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Industry-dominant profitability: Operating margin of 29.34% vs. industry average of 1.09% (2,590% premium) and net margin of 17.25% vs. industry average of -8.47% — HQY is profitable while the typical peer loses money; Q1 FY2027 net income of $69.4M (+29% YoY) confirms the earnings engine is firing. Main concern: Revenue growth of 7.2% trails the industry average of 20.62% by 13.4 percentage points — this structural gap limits multiple expansion and signals HQY is not gaining market share at the pace of peers; in a sector where top-line growth drives premium valuations, this persistent underperformance creates a structural valuation ceiling.
Investment Summary
HealthEquity (HQY) remains a high-quality compounder in the Healthcare Information Services sector, trading at $96.57 — up 9.2% from our prior entry recommendation of $88.46 eight days ago. The core investment thesis is intact: operating margin of 29.34% vs. industry average of 1.09% (a 2,590% premium), net margin of 17.25% vs. industry average of -8.47%, and FCF of $370M that substantially exceeds net income. The stock now trades at a PEG of 1.20 (up from 1.07 prior), reflecting the price appreciation without a corresponding earnings estimate upgrade. The analyst consensus target of $115.56 implies 19.7% upside from current levels — still meaningful but reduced from the prior 30.6% upside. Q1 FY2027 net income grew 29% YoY to $69.4M, confirming the earnings growth trajectory. The primary concern is that the stock has moved through our prior entry range ($86-$90) and now sits above it, requiring a reassessment of entry discipline. At $96.57, the risk/reward is less compelling than 8 days ago but still positive given the quality of the business. The PEG of 1.20 vs. industry average of 1.38 still represents a 13% discount to peers despite superior profitability — the valuation advantage persists, just at a slightly higher absolute level.
Key Strengths
- Industry-dominant profitability: Operating margin of 29.34% vs. industry average of 1.09% (2,590% premium) and net margin of 17.25% vs. industry average of -8.47% — HQY is profitable while the typical peer loses money; Q1 FY2027 net income of $69.4M (+29% YoY) confirms the earnings engine is firing
- Attractive valuation relative to peers despite superior fundamentals: P/E of 36.22 is 35.2% below the industry average of 55.87, and PEG of 1.20 is 13% below the industry average of 1.38 — the market is underpricing HQY's quality relative to loss-making competitors; analyst consensus target of $115.56 implies 19.7% upside
- Exceptional cash generation: FCF of $370.3M substantially exceeds net income, confirming high earnings quality and providing debt servicing capacity (D/E of 0.48) and strategic flexibility unavailable to most cash-burning peers; news sentiment of 94/100 with 12 positive articles reinforces positive business momentum
Key Concerns
- Revenue growth of 7.2% trails the industry average of 20.62% by 13.4 percentage points — this structural gap limits multiple expansion and signals HQY is not gaining market share at the pace of peers; in a sector where top-line growth drives premium valuations, this persistent underperformance creates a structural valuation ceiling
- Stock has appreciated 9.2% since prior report ($88.46 to $96.57), moving through the prior entry range and raising the PEG from 1.07 to 1.20 — the risk/reward has deteriorated modestly; cybersecurity risks remain a structural overhang for the trust-dependent HSA custodial business model (noted in news: 'Is HealthEquity's Improving Profitability Enough to Offset Key Risks?' — the 'key risks' reference likely includes data security vulnerabilities that could impair customer trust)
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
HQY's fundamentals remain exceptional and largely unchanged from the prior report. Gross margin of 62.64% (vs. industry 58.50%) confirms pricing power. Operating margin of 29.34% (vs. industry 1.09%) is the defining competitive moat. Net margin of 17.25% (vs. industry -8.47%) demonstrates that HQY is profitable while the average peer loses money. FCF of $370.3M exceeds net income, confirming high earnings quality. ROE of 11.06% is moderate but positive vs. industry average of -28.27%. Debt-to-equity of 0.48 is below the industry average of 0.61, indicating conservative leverage. P/E of 36.22 is 35.2% below the industry average of 55.87 — HQY is cheaper on earnings than loss-making peers. PEG of 1.20 vs. industry 1.38 — a 13% discount. Revenue growth of 7.2% trails industry average of 20.62% significantly (65.1% discount), which remains the primary structural weakness. Q1 FY2027 net income of $69.4M (+29% YoY) confirms the earnings growth trajectory is on track with the 14.7% 5-year EPS growth projection (historical 29.7% YoY EPS growth suggests the forward estimate may be conservative). The N/A next-year EPS estimate remains a data gap. Cash of $265M provides liquidity buffer against the $0.48 D/E leverage.
News Sentiment
HealthEquity is having a moment — and Wall Street is taking notice. The HSA (Health Savings Account) giant has been making headlines for all the right reasons, with multiple analysts and financial outlets highlighting the company as a standout growth story in the healthcare technology space. The biggest news: HealthEquity just reported Q1 FY2027 results showing net income jumped 29% year-over-year to $69.4 million — a number that tells you this company knows how to turn revenue into real profit. That's not easy in a sector where most competitors are still burning cash. Several headlines are singing HQY's praises. 'Here's Why HealthEquity (HQY) is a Strong Growth Stock' and 'Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term' both highlight the company's solid earnings trajectory and market position. Meanwhile, 'Reasons to Hold HealthEquity Stock in Your Portfolio for Now' suggests even cautious analysts see value here. The company's own research — 'One in Three Americans Delay Medical Care Due to Cost' — underscores the massive, unmet need that HSAs are designed to solve, validating the long-term market opportunity. Not everything is rosy, though. 'Is HealthEquity's Improving Profitability Enough to Offset Key Risks?' raises legitimate questions about cybersecurity vulnerabilities — a real concern for a company that holds sensitive health and financial data for millions of Americans. Bottom line: HealthEquity is a profitable, cash-generating machine in a sector full of money-losers, and the market is starting to recognize it.
Risk Assessment
Primary risks: (1) Valuation compression risk — PEG of 1.20 at P/E 36.22 leaves limited margin of safety; any growth disappointment below 14.7% 5-year EPS growth would compress the multiple significantly, with downside to $80-85 (PEG ~1.0) representing ~12-17% downside from current levels. (2) Revenue growth structural weakness — 7.2% vs. industry 20.62% limits multiple expansion; if revenue growth decelerates further, the earnings growth story (currently driven by margin expansion) becomes less sustainable. (3) Cybersecurity overhang — as an HSA custodian managing sensitive health and financial data, a material breach could impair customer trust and trigger regulatory action, representing a tail risk not captured in current multiples. (4) Price appreciation risk — the stock has moved 9.2% in 8 days, potentially pulling forward near-term returns; momentum-driven pullbacks to $90-93 are possible. Mitigation: Stop-loss at $87.50 (approximately 8.1% below entry midpoint of $95.25) limits downside; position sizing at 3.0% of portfolio reflects the reduced margin of safety vs. prior entry. The 2.6:1 risk/reward (upside to $115.56 vs. downside to $87.50) remains compelling for a quality compounder.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is HQY a halal stock?
No, HealthEquity, Inc. (HQY) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for HQY?
HealthEquity, Inc. (HQY) has a Plutrex AI rating of 79.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is HQY a good investment?
According to Plutrex AI, HQY has a Buy rating (79.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in HQY?
US stocks like HQY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in HQY?
Plutrex AI identifies the main risks for HQY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.